Molecular Staging, Inc. – Trademark Portfolio
Entity Type: 03
Molecular Staging, Inc. holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 10 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include REPLI-G. The owner is based in New Haven, CT.
300 George Street
New Haven, CT 06511
Showing of trademarks Trademarks
Trademark Classifications
Molecular Staging, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Molecular Staging, Inc. have?
Molecular Staging, Inc. has 12 U.S. trademarks filed with the USPTO. Of these, 2 registered, 9 abandoned, 1 cancelled.
What trademark classes does Molecular Staging, Inc. file in?
Molecular Staging, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 40 (Treatment & Processing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Molecular Staging, Inc.'s most well-known trademarks?
Molecular Staging, Inc.'s registered trademark portfolio includes well-known marks such as REPLI-G. These are among 2 currently registered trademarks in the portfolio.
What is Molecular Staging, Inc.'s trademark registration success rate?
Molecular Staging, Inc. has a 17% trademark registration rate, with 2 out of 12 resolved applications resulting in successful registration. Currently, 0 applications are pending review.